Nima J. Movahedi advises clients on a broad spectrum of complex corporate transactions, particularly in the aerospace & defense, technology, and life sciences sectors.

Mr. Movahedi leads boards and management with his extensive experience in complex financing and acquisition structures to guide private and public companies, venture capital and private equity firms, and investment banks on:

  • Mergers and acquisitions
  • Venture, growth capital, and private equity transactions
  • Structured equity, pre-IPO debt and equity financings, and similar private capital transactions
  • Public and private securities offerings and securities law compliance
  • Early-stage formation and corporate strategy
  • Employment matters and equity incentives
  • Restructuring and special situations

He helps corporate clients navigate challenges that arise on the path to exit, and leverages access to the full resources of Latham’s global platform to address key issues in sophisticated cross-border transactions.

Mr. Movahedi’s representative experience includes advising:

Mergers & Acquisitions

  • Icosavax on its US$1.1 billion sale to AstraZeneca
  • Skrewball on selling a majority stake to Pernod Ricard
  • Ouster on its US$400 million merger of equals with Velodyne Lidar
  • Virgin Orbit on its US$3.2 billion merger with NextGen Acquisition Corp. II
  • Offerpad on its US$3 billion merger with Supernova Partners Acquisition Company
  • Owlet on its US$1.4 billion merger with Sandbridge Acquisition Corp.
  • Latch on its US$1.6 billion merger with TS Innovation Acquisitions Corp.
  • Talkspace on its US$1.6 billion merger with Hudson Executive Investment Corp.
  • Ouster on its US$1.9 billion merger with Colonnade Acquisition Corp.
  • GCM Grosvenor on its US$2 billion merger with CF Finance Acquisition Corp.
  • Cryoport on its US$320 million acquisition of Chart Industries’ cryobiological products business
  • Virgin Galactic on its US$1.5 billion merger with Social Capital Hedosophia Holdings
  • The Committee of Independent Directors of T-Mobile US on its US$146 billion merger between T-Mobile US and Sprint
  • Impact Biomedicines on its up to US$7 billion sale to Celgene
  • PIMCO on acquiring Gurtin Municipal Bond Management
  • ICU Medical on its US$900 million acquisition of Pfizer’s Hospira Infusion Systems business
  • Breathe Technologies on its US$130 million sale to Hill-Rom
  • Mission Lane on acquiring LendUp’s credit cards business
  • Putney on its US$200 million sale to Dechra Pharmaceuticals

Venture, Growth Capital, and Private Equity

  • a16z
  • Eclipse Ventures
  • Goldman Sachs
  • Great Hill Partners
  • Invus
  • KKR
  • L Catterton
  • Lightspeed Venture Partners
  • Meritech Capital Partners
  • Novo Ventures
  • Virgin Investments

Emerging Companies

  • Aerospace & Defense / Mobility
    • Amphenol
    • Joby Aviation
    • Shield AI
    • Virgin Galatic
    • Virgin Hyperloop
    • Virgin Orbit
    • ZeroAvia
  • Technology
    • Advantage Data
    • Agrovision
    • Aspiration
    • Blueground
    • Bolt Threads
    • Evergent
    • GrooveLabs
    • Higher Grounds Education
    • Latch
    • LogMeIn
    • Mosaic Building Group
    • Newlight
    • Offerpad
    • Omio
    • Ouster
    • Owlet
    • Syntiant
    • Talkspace
    • Truepill
    • X-energy
  • Life Sciences
    • AcuFocus
    • Alcresta
    • Ambry Genetics
    • Cercacor
    • Equinox Ophthalmic
    • Hart
    • Immunis
    • Impact Biomedicines
    • Invoy
    • Mineralys
    • Regeneration Biomedical
    • Relievant Medsystems
    • Saluda
    • SQZ Biotechnologies
    • 10x Health
  • Retail
    • Beauty Health
    • Incipio
    • Skrewball

Bar Qualification

  • California


  • JD, Boston University School of Law
    cum laude
  • BA, University of California, Los Angeles
    Dean's List

Languages Spoken

  • English
  • Farsi (Persian)